Abstract:Abstract Background Empagliflozin (EMPA) is a widely used medication in the treatment of Type 2 diabetes Mellitus (T2DM). It functions by inhibiting glucose reabsorption by the kidneys, which helps lower blood glucose levels. Studies have shown that there is a bidirectional relationship between oral medications and the gut microbiota. The gut microbiota is one of the most complex and diverse microbial communities in the body, with dysbiosis being closely associated with various metabolic diseases, such as diabetes, obesity, and cardiovascular diseases. Therefore, the aim of this study was to investigate the effects of EMPA on the gut microbiota of T2DM mice, in order to further elucidate its potential roles in blood glucose control and cardiovascular protection. Methods and Results We intervened with db/db mice for 20 weeks, measuring blood glucose during the intervention and blood lipids after the intervention. We collected fecal samples from the mice before and after the intervention, ensuring that the samples were uncontaminated by collecting them from the anus. Through bioinformatics analysis using 16S rRNA sequencing, we identified changes in key genus of gut microbiota in these mice. In addition to the conventional abilities of reducing blood glucose and blood lipids, we found that the impact of EMPA on gut microbiota could not be ignored. EMPA significantly changed the diversity and richness index of gut microbiota in db/db mice, such as the sobs and simpsons index. EMPA changed the β-diversity of gut microbiota, altering the complexity between different bacterial genus to be similar to that of healthy mice. EMPA also increased the abundance of species such as Clostridium_innocuum_group, Rikenellaceae, Alistipes, Prevotellaceae_UCG-001, Eubacterium_siraeum_group, Anaeroplasma, and Odoribacter, while decreasing the abundance of species such as Eubacterium_ventriosum_group, Fusobacterium, Hydrogenoanaerobacterium, Tyzzerella, Prevotellaceae_NK3B31_group, Aerococcaceae, and Aerococcus. Spearman correlation networks analysis showed that Alistipes, Odoribacter, and Anaeroplasma were significantly negatively correlated with blood glucose levels, while Aerococcus was significantly positively correlated with Total cholesterol (TC) and Total triglycerides (TG). EMPA also reduced the functional abundance of gut microbiota related to "Membrane transport," "Xenobiotics biodegradation and metabolism," and "Immune disease." EMPA may achieve its partial blood glucose-lowering and cardiovascular disease-improving effects by impacting these key species and functional abundance of gut microbiota. Conclusion In conclusion, our 20-week intervention on db/db mice showed that EMPA not only had a significant impact on blood glucose and lipids but also on the diversity and richness of gut microbiota. EMPA altered the abundance and ratio of Firmicutes and Bacteroidota, increased beneficial species, and decreased harmful ones. Spearman network analysis revealed the correlation between specific gut microbes and blood glucose and lipid levels. EMPA also decreased the functional abundance of "Membrane transport," "Xenobiotics biodegradation and metabolism," and "Immune disease" pathways. Our findings suggest that EMPA's therapeutic effects may partly arise from its modulation of gut microbiota.

Integrated Multi-Omics Analyses Reveal Effects of Empagliflozin on Intestinal Homeostasis in High-Fat-diet Mice

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease

Empagliflozin attenuates liver fibrosis in high‐fat diet/streptozotocin‐induced mice by modulating gut microbiota

The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice

Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora

Empagliflozin Modify Gut Microbiota in Db/db Mice Correlating with the Improvement of Glucose and Lipid Metabolism

Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice

Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice

Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice

Empagliflozin treatment differentially modifies visceral and subcutaneous adipose tissue lipidomes and pro-inflammatory cytokines in zucker fatty diabetic rats

The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

Reno-protective Effects of Empagliflozin in High Fat Diet Induced Obesity-Related Glomerulopathy by Regulation of Gut-Kidney Axis

Empagliflozin Ameliorates Type 2 Diabetes Mellitus-Related Diabetic Nephropathy Via Altering the Gut Microbiota

Renal Metabolome in Obese Mice Treated with Empagliflozin Suggests a Reduction in Cellular Respiration

Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism

Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis